The headlines are everywhere: a new class of weight loss medications is producing results that doctors haven’t seen in decades. But buried beneath the excitement is a question that millions of Americans are confronting every month — can I actually afford this?

The short answer is: it depends. The longer answer involves manufacturer coupons, insurance battles, compounding pharmacies, and a rapidly shifting policy landscape. Let’s break it all down.

What These Drugs Actually Cost (Without Help)

The list prices for GLP-1 and dual GLP-1/GIP medications are eye-watering:

• Ozempic (semaglutide, for diabetes): ~$935/month
• Wegovy (semaglutide, for weight loss): ~$1,350/month
• Mounjaro (tirzepatide, for diabetes): ~$1,023/month
• Zepbound (tirzepatide, for weight loss): ~$1,060/month

These are list prices — what you’d pay without insurance or any assistance program. For the vast majority of patients, these prices are simply not sustainable long-term.

What Insurance Actually Covers

Coverage is inconsistent, fragmented, and often infuriating.

For diabetes medications (Ozempic, Mounjaro): Coverage is generally better. Most commercial insurance plans include these on their formularies because diabetes management is widely recognized as medically necessary. Co-pays with insurance can range from $25 to $200 per month depending on your plan and tier placement.

For weight loss medications (Wegovy, Zepbound): This is where coverage falls apart. An estimated half of commercial insurance plans still do not cover anti-obesity medications. The reasoning, though increasingly challenged by medical experts, has historically been that obesity treatment is considered “lifestyle” rather than disease management.

Medicare: Standard Medicare Part D does not cover weight loss drugs, full stop — though legislation to change this has been introduced and debated in Congress. This leaves millions of seniors without access to these medications.

Medicaid: Coverage varies widely by state. Some states cover GLP-1s for obesity; many do not.

Manufacturer Savings Programs

This is often the first lifeline for patients.

Eli Lilly (maker of Mounjaro and Zepbound) offers savings cards:

• Eligible commercially insured patients may pay as little as $25/month for Mounjaro
• Zepbound savings cards can reduce costs to $550/month or less for eligible patients
• These programs are not available for Medicare or Medicaid recipients

Novo Nordisk (maker of Ozempic and Wegovy) offers similar programs:

• Wegovy savings card: eligible patients may pay around $0–$650/month
• NovoCare patient assistance program for uninsured/underinsured patients

These programs have income limits and eligibility requirements, and they are subject to change — so always verify directly with the manufacturer.

Compounding Pharmacies: The Controversial Workaround

When the FDA placed semaglutide and tirzepatide on its drug shortage list, a new market exploded: compounding pharmacies began producing their own versions of these medications at significantly lower prices — sometimes as little as $200–$400/month.

Compounded semaglutide and tirzepatide are technically legal under shortage provisions, but they come with important caveats:

• Not FDA-approved: Compounded versions haven’t gone through the same efficacy and safety testing as brand-name drugs
• Quality varies: Some compounding pharmacies are licensed and reputable; others are not
• Added ingredients: Some compounds include additives (like B12 or L-carnitine) with unproven benefits
• Legal gray zone: As the FDA has moved to remove semaglutide from the shortage list, the legal status of compounded versions has become contested, with lawsuits from both compounders and manufacturers

If you’re considering a compounding pharmacy, look for ones accredited by the PCAB (Pharmacy Compounding Accreditation Board) and work closely with your physician.

Prior Authorization: The Insurance Hurdle

Even when your plan technically covers a GLP-1 medication, getting it approved is rarely automatic. Most insurers require prior authorization, which typically means your doctor must document:

• Your BMI and any weight-related comorbidities
• That you’ve attempted lifestyle interventions (diet and exercise) without sufficient results
• Medical necessity based on clinical guidelines

This process can take days to weeks, and denials are common. If you’re denied, don’t give up — the appeals process succeeds more often than patients expect, especially with a letter of medical necessity from your physician.

Practical Strategies to Lower Your Costs

1. Ask your doctor to check both Mounjaro and Zepbound — if you have type 2 diabetes, the diabetes indication may be covered when the weight loss indication isn’t
2. Use manufacturer savings cards even if you have insurance — they can apply to your co-pay in some cases
3. Check GoodRx and similar platforms for pharmacy-specific discounts
4. Ask about patient assistance programs if you’re uninsured or underinsured — manufacturers have programs for qualifying patients
5. Work with your doctor on prior authorization and be prepared to appeal denials
6. Ask about telehealth weight management platforms — some negotiate lower rates with pharmacies
7. Follow policy changes — coverage landscapes are evolving quickly, and your plan’s formulary may update annually

What’s Changing

The landscape is shifting, and not slowly. Employers, recognizing the potential long-term savings from treating obesity, are beginning to add GLP-1 coverage for weight loss. Several large corporations have added Wegovy or Zepbound to their benefits packages. Congress has repeatedly debated the Treat and Reduce Obesity Act, which would expand Medicare coverage. And as biosimilars and generic competition eventually enter the market, prices are expected to fall.

The Bottom Line

Access to GLP-1 medications for weight loss remains deeply unequal. Those with employer-sponsored insurance and higher incomes have far more options than those on government programs or without coverage. Until the policy landscape catches up with the science, navigating these medications requires persistence, advocacy, and knowing every option available to you.

If cost is a barrier, start with your doctor, then contact the manufacturer, then explore every assistance program before ruling out treatment.

Disclaimer: Prices and program eligibility change frequently. This article reflects general information and should not be taken as current pricing or insurance guidance. Always verify with your insurer, pharmacist, and physician.